Evidence map›Paper›PMID 37881541›Full record

ArticleBiological psychiatry global open science2023

Daisy L Spark, Michela H Vermeulen, Rocío A de la Fuente Gonzalez, Cassandra J Hatzipantelis, Patricia Rueda, Tara Sepehrizadeh, Michael De Veer, Clotilde Mannoury la Cour, Alex Fornito, Monica Langiu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry global open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Daisy L SparkDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Michela H VermeulenDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Rocío A de la Fuente GonzalezDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Cassandra J HatzipantelisOlson Lab, Department of Chemistry, University of California, Davis, California.
Patricia RuedaDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Tara SepehrizadehMonash Biomedical Imaging, Monash University, Clayton, Victoria, Australia.
Michael De VeerMonash Biomedical Imaging, Monash University, Clayton, Victoria, Australia.
Clotilde Mannoury la CourNeuroscience and Inflammation Therapeutic Area, Institut de Recherches Servier, Suresnes, France.
Alex FornitoTurner Institute for Brain and Mental Health, Monash Biomedical Imaging, and School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.
Monica LangiuDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Gregory D StewartDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Jess NithianantharajahFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Christopher J LangmeadDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Monash University · AUServier (France) · FRThe University of Melbourne · AUUniversity of California, Davis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Disrupted motivational control is a common-but poorly treated-feature of psychiatric disorders, arising via aberrant mesolimbic dopaminergic signaling. GPR88 is an orphan G protein-coupled receptor that is highly expressed in the striatum and therefore well placed to modulate disrupted signaling. While the phenotype of Methods: In male and female Results: We showed that male and female Conclusions: Our results highlight that GPR88 regulates motivational control but that disruption of such behaviors following

Indexed as

DopamineGPR88MotivationOrphan G protein–coupled receptorStriatumTouchscreen

Identifiers

PMID37881541
PMCPMC10593871
OpenAlexW4309047767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.